The mammalian cyclin-dependent kinase inhibitor (CDKI) p27 is a potent regulator of cell cycle arresting transition from G 1 to S phase. In contrast to earlier opinion of mere cytoplasmic incapacitation of p27, there is a growing body of evidence suggesting that p27 could be transformed from a native CDKI into a dynamic oncoprotein at the expense of its extranuclear localization in leukemic cells. Emerging concepts also indicate that there are certain resident leukemic stem cells (LSC) in bone marrow milieu, which possess exuberant self-renewal characteristics and they eventually lead to conventional therapeutic recalcitrance. Given that BCR-ABL-containing CD34 þ cells successfully persist in chronic myeloid leukemia (CML) patients with cytogenetic remission under imatinib, it is necessary to elucidate additional incongruous molecular program that might have significant therapeutic implications. In this connection, considering the functional nexus among p27, BCR-ABL and a transmembrane glycoprotein CD44 in the regulation of homing, engraftment and proliferation of LSCs together with the recent findings that p27 can promote cellular migration and metastasis in several other malignancies, [1] [2] [3] [4] it could be pertinent to address the possibilities of p27 pleiotropism in regenerative and preventive medicine.
During G 0 -to S-phase transition, p27 proteolysis requires intact p27-cyclin-cdk trimeric motif. Cdk2-dependent phosphorylation of p27 at T187 promotes Skp1-Cul1-F-box (SCF Skp2 ) ubiquitin Ligase-mediated degradation of p27. In early G 1 T187-independent p27, proteolysis can also take place that involves Skp2-dependent and Skp2-independent mechanisms. However, proteolysis of cytoplasmic pool of p27 in G 1 sometimes involves a different Kip1 ubiquitination promoting complex ubiquitin ligase. Furthermore, in early G 1 , phosphatidylinositol-3-kinase (PI3K)-dependent phosphorylation at T157 on the nuclear localization signal of p27 promotes cytoplasmic sequestration. In addition, molecular control of transcription, mRNA stabilization and protein degradation might all act in concert to impinge on the biological functions of p27.
CML is a clonal, myeloproliferative and multiphasic stem cell disorder of hematopoietic development. Transformation by p210 BCRÀABL is a complex mechanism, implicating enhanced proliferation and inhibition of apoptosis, but conserved differentiation particularly in the initial chronic phase of the disease. 5, 6 Paradoxically, blast crisis CML is marked with acute differentiation blockages. Although BCR-ABL has been one of the primary transforming events responsible for CML development, there are other associated deregulated molecular checkpoints that play important role in the blast transformation, thus rendering them as putative therapeutic targets. Nevertheless, prioritization of such extra BCR-ABL secondary transformationderived therapeutic targets is not only crucial for preventive medicine but to a better understanding of the molecular mechanisms of CML blast transformation. Interestingly, several lines of evidence indicate involvement of deregulated p27 as one of such crucial events in leukemogenesis (Table 1) . Emerging evidence indicates that BCR-ABL-mediated CML CD34 þ cell proliferation is intertwined with the nucleocytoplasmic distribution of p27. BCR-ABL-induced constitutive activation of PI3K in CML cells causes p27 T157 phosphorylation and results in its cytoplasmic sequestration. PI3K can also promote downregulation of p27 both by suppression of synthesis and stimulation of protein degradation. Indeed, it has been demonstrated that unlike in normal CD34 Abbreviations: AML, acute myeloid leukemia; CML, chronic myeloid leukemia.
Letters to the Editor progression and the proliferative advantage is synchronized with cytoplasmic sequestration of p27. 7 Therefore, since BCR-ABL is considered as a hallmark of CML development, the manner in which it regulates p27 stability warrants future investigations. Likewise, whether BCR-ABL is responsible for relocation and functional inactivation or constitutive activation of other molecules that might regulate cell growth needs to be examined.
Furthermore, p27 can also be deregulated by constitutive Y88 phosphorylation in BCR-ABL-expressing leukemias. Recently it has been shown that nonreceptor cytoplasmic tyrosine kinase Lyn induces phosphorylation of p27 (p27-cyclin-cdk trimeric motif) in vitro in its N-terminus cdk-inhibitory domain at Y88. 8 Eventually p27 is transformed into a cdk-substrate and thus is triggered for SCF Skp2 -dependent degradation. Although the intrinsic flexibility of p27 has been ascribed for this phosphorylation, it is still to validate whether such mechanism really exists in vivo. Given that blast crisis CML is accompanied by enhanced Lyn expression, future studies could be considered to address whether other members of the Src family of tyrosine kinases, such as Fyn or Yes, can exert similar effect. In addition, even in the blast-phase CML cells, there could be a moderate pool of p27 sequestered in the cytoplasm and it also remains to be seen whether that could be putative targets of other nonreceptor kinases.
Several studies carried out on malignant hematopoiesis over the last few years have bolstered putative involvement of dynamic LSC compartments in chronic and acute leukemias. Considering BCR-ABL-induced cytoplasmic mislocalization of p27 in CML cells one can hypothesize whether this is a mere aftermath of CDKI inactivation or this sequestration is a paradigm in CML stem cell biology. In other words, is deregulated redistribution of p27 in CML simply analogous to the loss of CDKI and/or tumor suppressive function or oncoprotein-like functions that are programmatically acquired in CML cytoplasm? Similarly, considering the studies based on the analysis of normal/tumor stem cell samples and CDKI knockout mouse models, one can not rule out the possibilities of deregulation of other CDKIs in LSC transformation. 9 It has been suggested that downregulation of p18 along with disruption of p15 and p16 through promoter hypermethylation could act as secondary transforming events that might set the platform of LSC transformation to outcompete normal hematopoiesis. Furthermore, given that both normal and tumor stem cells can share Bmi-1-and b-catenin-mediated self-renewal and p16/p19 can partially mediate the role of Bmi-1 in the cell cycle of stem cells, it remains to be elucidated whether b-catenin or other selfrenewal pathways might involve CDKI functioning during CML development. 9 Recently we have demonstrated that deregulation and cross-talk among Sonic hedgehog, Wnt, Hox and Notch signaling during CML progression accompanies with dynamic changes in p21 and p27. 10 Moreover, acute overexpression of a stable p27 molecule had a promising edge in CML therapeutics. 11 It is thus becoming increasingly evident that p27 and other CDKIs can play distinct roles, depending on the sub-compartments of the hematopoietic cascade they belong. In addition, epigenetic control of gene expression and microRNA-mediated post-transcriptional regulation at the primitive stem cell level might produce an additional degree of complexity in making regulated/deregulated self-renewal and differentiation associated with normal and malignant hematopoiesis. 12 Nonetheless, LSC might exploit these subtleties necessary for hematopoietic stem cell (HSC) maintenance in making deregulated p27, be it as a secondary transforming event but necessary for CML development.
Another important aspect in the context of LSC is how p27 can control their homing, engraftment and niche-dependent maintenance of the tumor burden. Recent studies demonstrate that BCR-ABL-expressing LSCs depend to a larger extent on CD44 for their homing and engraftment into bone marrow microenvironmental niche than do normal HSCs; therefore, CD44 blockage might be beneficial in autologous transplantation for CML. 1 Notably, CML cells do have functional defects in b 1 -integrin and stromal cell-derived factor-1-mediated adhesion and transmigration, which are indicative of alternative adhesive mechanisms necessary for LSC engraftment. Indeed, BCR-ABL induces expression of functional E-selectin ligands on LSCs partially by upregulation of the hyaluronan receptor CD44. CD44 ligation can also lead to eradication of acute myeloid leukemia stem cells that includes pro-differentiation. 1 Then again, CD44-dependent differentiation therapy is accompanied by enhanced p27 stability.
2 Therefore considering deregulated p27 associated with CML, it might be important to investigate the BCR-ABL-p27-CD44 axis in CML stem cell-niche interaction (Figure 1 ).
In addition, p27 has been suggested to regulate cellular migration in a spatiotemporal manner, which is an important aspect in tumor metastasis. Interestingly, this notion gets a sudden impetus when it was reported that cytoplasmic p27 could interfere with RhoA activation by guanine-nucleotideexchange factors through its C terminus and thereby regulating cellular migration. 4 Rho proteins regulate and coordinate the cytoskeletal remodeling that underlies changes in cell adhesion and migration. CML is linked with modifications of the actin cytoskeleton, and BCR-ABL is preferentially associated with Factin and its distribution changes in migrating cells. Recently it Figure 1 Model to show integration of different BCR-ABL-p27 axes in CML stem cell regulation. BCR-ABL induces expression of CD44 in CML stem cells. The transmembrane glycoprotein CD44 can stabilize p27 in an intriguing manner (dotted line). In addition, nuclear localization of p27 is usually inhibited by BCR-ABL resulting cytoplasmic pool of p27. Taken together, BCR-ABL-p27-CD44 axis might be responsible for abnormal CML stem cell proliferation. On the other hand, BCR-ABL can lead to cytoplasmic remodeling and CML stem cell homing by RhoGTPase activation. Furthermore, p27 can regulate cell migration and metastatic potential of other tumors through RhoA interaction (dotted line). All together, BCR-ABL-p27-RhoGTPase axis can regulate CML stem cell homing, engraftment and proliferation. CML, chronic myeloid leukemia.
has been reported that, in contrast to p190 BCRÀABL that is normally found in Ph þ ALL, CML associated p210 BCRÀABL by virtue of its unique Dbl/Plecstrin-homology domain, can bind to small GTPases of the Rho family both in vitro and in vivo.
3 This in turn gives rise to Rho activation, which might be responsible for promoting cellular motility. Taken together, it need to be substantiated whether or not these events do indeed contribute to malignant transformation; however, considering BCR-ABLinduced abundant pool of p27 in the CML cytoplasm, one can at least speculate the involvement of BCR-ABL-p27-RhoGTPase axis in CML blast transformation (Figure 1 ).
Past few decades have witnessed considerable advancement in identifying putative phosphorylation hotspots in p27 that are important for cell cycle regulation. The N-terminus portion of p27 is recruited to cyclin-cdk complexes and results in cell cycle arrest and it is the C-terminus portion that can promote cellular motility and thus metastatic potential. Intriguingly, these two functions are virtually partitioned by a single parameter: the address of p27 at a given point of time. Future studies could be directed to unravel the individual domain contribution by using respective knockout animal models, and it would be important to look upon whether tampering p27 in such a manner can have any consequences on cancer predisposition. Furthermore, different CDKIs control diverse array of functions for HSC maintenance. However, we know very little about how these different CDKIs differentially regulate quiescence, self-renewal and homing, three important aspects of regenerative medicine, of normal and malignant HSCs. To conclude, we are only beginning to appreciate the underlying importance of p27 and other cell cycle inhibitors in the context of LSCs. Indeed, how such an intrinsically unstructured p27 protein governs CML biology need to be explored further.
No evidence for amplification of V617F JAK2 in myeloproliferative disorders Acquired uniparental disomy following mitotic recombination results in homozygosity for the V617F JAK2 mutation in a proportion of patients with myeloproliferative disorders (MPD), particularly polycythemia vera (PV) and myelofibrosis (MF). 1 Recently, Hammond et al.
2 in a letter in Leukemia indicated that a proportion of MPDs harbor more than two copies of V617F JAK2 and suggested that disease evolution may involve further gene duplication associated with genetic instability. In a followup study, the same group found that this phenomenon was most prevalent in PV, with more than one-third of mutation-positive cases apparently having more than two V617F copies/cell. 3 Increased V617F copy number has been described in cell lines, 4 but has not thus far been verified in patients.
To determine if elevated JAK2 copy number could be detected with an alternative methodology, we developed a test based on multiplex ligation-dependent probe amplification (MLPA), an established technique for detecting DNA copy number changes. [5] [6] [7] Four MLPA probe pairs targeting JAK2 exons 3, 9, 16 and 20 were designed, so that they could be combined with the commercially available telomere MLPA probe mix (P036B
